<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2601">
  <stage>Registered</stage>
  <submitdate>8/12/2009</submitdate>
  <approvaldate>8/12/2009</approvaldate>
  <nctid>NCT01027871</nctid>
  <trial_identification>
    <studytitle>A Study for Patients With Type 2 Diabetes</studytitle>
    <scientifictitle>A Phase 2 Study of LY2605541 Compared With Insulin Glargine in the Treatment of Type 2 Diabetes Mellitus</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>I2R-MC-BIAC</secondaryid>
    <secondaryid>12149</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Mellitus, Type 2</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - LY2605541
Treatment: drugs - insulin glargine

Experimental: LY2605541 Dosing Algorithm 1 - 

Experimental: LY2605541 Dosing Algorithm 2 - 

Active Comparator: Insulin glargine - 


Treatment: drugs: LY2605541
subcutaneous injection of LY2605541 every morning with dose titration based on blood glucose measures for 12 weeks

Treatment: drugs: insulin glargine
subcutaneous injection of insulin glargine every morning with dose titration based on blood glucose measures for 12 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Fasting blood glucose at 12-week endpoint of treatment as measured by the 8-point self-monitored blood glucose profiles</outcome>
      <timepoint>Week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in fasting blood glucose from baseline to 12-week endpoint</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HbA1c change from baseline to 12-week endpoint</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients with HbA1c &lt;7.0% and less than or equal to 6.5% at 12-week endpoint</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients with HbA1c &lt;7.0% and HbA1c less than or equal to 6.5% at 12-week endpoint who did not experience a hypoglycemic episode during treatment</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>8-point self-monitored blood glucose measures at 12-week endpoint</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Daily basal insulin dose</outcome>
      <timepoint>Baseline, Weeks 2, 4, 6, 8, 10, 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients with hypoglycemia from baseline to Week 12</outcome>
      <timepoint>Baseline to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of hypoglycemia per 30 days from baseline to Week 12</outcome>
      <timepoint>Baseline to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>LY2605541 antibody titers</outcome>
      <timepoint>Baseline, Week 12 , and Week 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Variability in fasting blood glucose</outcome>
      <timepoint>Baseline, Weeks 2, 4, 6, 8, 10, 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics - Concentration at steady state (Css)</outcome>
      <timepoint>Baseline, Weeks 4, 8, 10, 12, and 16</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in fasting blood glucose from baseline to 12-week endpoint - subgroup analysis of LY2605541 dosing algorithms</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HbA1c change from baseline to 12-week endpoint - subgroup analysis of LY2605541 dosing algorithms</outcome>
      <timepoint>Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients with HbA1c &lt;7.0% and less than or equal to 6.5% at 12-week endpoint - subgroup analysis of LY2605541 dosing algorithms</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients with HbA1c &lt;7.0% and HbA1c less than or equal to 6.5% at 12-week endpoint who did not experience a hypoglycemic episode during treatment - subgroup analysis of LY2605541 dosing algorithms</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>8-point self-monitored blood glucose measures at 12-week endpoint - subgroup analysis of LY2605541 dosing algorithms</outcome>
      <timepoint>Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Daily basal insulin dose - subgroup analysis of LY2605541 dosing algorithms</outcome>
      <timepoint>Baseline, Weeks 2, 4, 6, 8, 10, and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients with hypoglycemia from baseline to Week 12 - subgroup analysis of LY2605541 dosing algorithms</outcome>
      <timepoint>Baseline to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of hypoglycemia per 30 days from baseline to Week 12 - subgroup analysis of LY2605541 dosing algorithms</outcome>
      <timepoint>Baseline to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Variability in fasting blood glucose - subgroup analysis of LY2605541 dosing algorithms</outcome>
      <timepoint>Baseline, Weeks 2, 4, 6, 8, 10, and 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Type 2 diabetes mellitus (T2DM) for at least 1 year

          -  At least 18 years of age

          -  Using metformin and/or sulfonylurea(s) with once daily glargine or NPH for at least 3
             months prior to the study. Prestudy dose requirements: insulin dose maximum 1.0
             U/kg/day. Oral antihyperglycemic medications (OAMs): Metformin dose at least 1500
             mg/day and/or sulfonylurea dose at least half the maximum daily dose specified in the
             local package insert. OAM doses stable for 6 weeks prior to the study.

          -  HbA1c less than or equal to 10.5% before randomization

          -  BMI 19 to 45 kg/m2

          -  Capable and willing to prepare and inject insulin with a syringe while continuing to
             use the prestudy OAMs, monitor own blood glucose; complete the study diary; be
             receptive to diabetes education; comply with study visits and receive telephone calls
             between visits

          -  Women of childbearing potential must test negative for pregnancy before receiving
             treatment and agree to use reliable birth control until completing the follow-up visit</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Long-term use of short- or rapid-acting or premixed insulin within the 6 months before
             the study. Short-term insulin therapy or occasional use are permitted

          -  Use of any glucose-lowering medications not allowed by the inclusion criteria in the 3
             months before entry into the study

          -  Use of prescription or over-the-counter medications to promote weight loss within 3
             months before entry into the study

          -  Current participation in a weight loss program, or plans to do so during the study

          -  Treatment with any antibody-based therapy within 6 months prior to the study

          -  Use of chronic (&gt;14 consecutive days) systemic glucocorticoid therapy currently or
             within 4 weeks prior to the study

          -  More than 1 episode of severe hypoglycemia within 6 months prior to the study, or
             currently diagnosed with hypoglycemia unawareness

          -  2 or more emergency room visits or hospitalizations due to poor glucose control in the
             6 months preceding the study

          -  Liver disease

          -  History of renal transplantation, current renal dialysis, or creatinine &gt;2.0 mg/dL
             (177 Âµmol/L)

          -  Cardiac disease with a marked impact on physical functioning

          -  Clinically significant ECG abnormalities at screening

          -  Malignancy other than basal cell or squamous cell skin cancer

          -  Fasting triglycerides &gt;500 mg/dL

          -  Known diabetic autonomic neuropathy

          -  Known hypersensitivity or allergy to study insulin or its excipients

          -  Blood transfusion or severe blood loss within 3 months prior to entry into the study
             or known hemoglobinopathy, hemolytic anemia, or sickle cell anemia, or any other
             traits of hemoglobin abnormalities known to interfere with the HbA1c methodology

          -  Irregular sleep/wake cycle

          -  Women who are breastfeeding</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>131</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC,WA</recruitmentstate>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Coffs Harbour</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Keswick</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - East Ringwood</hospital>
    <hospital>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Fremantle</hospital>
    <postcode>2450 - Coffs Harbour</postcode>
    <postcode>5035 - Keswick</postcode>
    <postcode>3135 - East Ringwood</postcode>
    <postcode>6160 - Fremantle</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Gyula</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Veszprem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Hato Rey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Manati</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Cluj-Napoca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Iasi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Targu Mures</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Arkhangelsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Rostov-On-Don</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Dos Hermanas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Malaga</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eli Lilly and Company</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Comparison of fasting blood glucose levels in patients with Type 2 diabetes after 12 weeks of
      treatment with a new basal insulin analog or with insulin glargine.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01027871</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>